Skip to content
Search

Latest Stories

NHS England announces new executive team to lead transformation

NHS England restructures leadership with new executive team

Except for the deputy chief executive officer, all team members will assume their roles on 1 April 2025.

Getty Images

Sir James Mackey will be leading NHS England’s transition into the Department of Health and Social Care (DHSC), along with the incoming team.

He will officially take up the role as the new chief executive officer of NHS England on 1 April 2025, replacing Amanda Pritchard, who is stepping down at the end of this month.


On Monday, NHSE announced the NHS Transformation Executive Team, which will replace the current executive group.

The organisation said that the new team, composed of leaders from within the NHS and seconded roles, has been appointed following discussions with the health secretary Wes Streeting, DHSC officials, incoming Chair Dr Penny Dash, and the NHS England Board.

As part of the restructuring, the roles of chief operating officer and chief delivery officer have been removed.

Instead, the new structure introduces two co-medical directors, and new positions such as a financial reset and accountability director and elective care, cancer and diagnostics director.

NHS Transformation Executive Team

  • Sir James Mackey – chief executive officer, responsible for overall accountability and leadership of the organisation. Temporarily, he will also oversee HR, OD and corporate operations; privacy, transparency and trust; legal; corporate governance; performance and delivery unit; inquiries; mental health, learning disability and autism.
  • David Probert - Deputy CEO
  • Meghana Pandit- Co-Medical Director – Secondary Care
  • Claire Fuller - Co-Medical Director – Primary Care
  • Duncan Burton- Chief Nursing Officer
  • Elizabeth O’Mahony - Chief Financial Officer
  • Glen Burley - Financial Reset Director and Accountability Director
  • Mark Cubbon - Elective Care, Cancer and Diagnostics Director
  • Vin Diwakar- Clinical Transformation Director
  • Sarah-Jane Marsh - Urgent and Emergency Care Director
  • Dr. Amanda Doyle- National Director of Primary Care and Community Services

Additionally, seven regional directors have been appointed:

  • Anne Eden – South East
  • Claire Panniker – East
  • Dale Bywater – Midlands
  • Fiona Edwards – North East and Yorkshire
  • Louise Shepherd – North West
  • Caroline Clarke – London
  • Sue Doheny (acting) – South West

Except for the deputy chief executive officer, all team members will assume their roles on 1 April 2025 to support ongoing business priorities, statutory functions, and day-to-day operations.

Glen Burley, Mark Cubbon and David Probert will continue their current trust roles alongside their new roles within the Transformation Executive Team.

Professor Stephen Powis will remain in his role as national medical director until early July, working closely with Meghana Pandit and Claire Fuller to finalise arrangements for the medical directorate.

Regional Directors will report directly to Sir Mackey, as will Navina Evans (chief workforce, training and education officer) and Chris Hopson (chief strategy officer).

A new substantive chief digital officer is expected to be recruited soon.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less